How many drugs treat herpes zoster keratitis?

Drug Landscape tracks 10 marketed treatments for herpes zoster keratitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/herpes-zoster-keratitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

herpes zoster keratitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

herpes zoster keratitis (disease) competitive landscape: 10 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

10 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating herpes zoster keratitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Loteprednol Etabonate	LOTEPREDNOL	Bausch And Lomb			2020-01-01
Lotemax	LOTEPREDNOL ETABONATE	Bausch Health	Corticosteroid	Glucocorticoid receptor	1998-01-01
Flarex	FLUOROMETHOLONE ACETATE	Harrow Health	Corticosteroid	Glucocorticoid receptor	1986-01-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Fml	FLUOROMETHOLONE	AbbVie	Corticosteroid	Glucocorticoid receptor	1972-01-01
Medrifar	MEDRYSONE	AbbVie	Corticosteroid	Glucocorticoid receptor	1969-01-01
Decadron	dexamethasone	Generic (originally Merck)	Corticosteroid [EPC]	Annexin A1, Interleukin-4, Androgen receptor	1958-10-30
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
Cortef	hydrocortisone	Generic (originally Merck/Upjohn)	Corticosteroid [EPC]	Annexin A1, Corticosteroid-binding globulin, Nitric oxide synthase, inducible	1952-01-01
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

· 2 drugs in herpes zoster keratitis
AbbVie · 2 drugs in herpes zoster keratitis
Bausch And Lomb · 1 drug in herpes zoster keratitis
Bausch Health · 1 drug in herpes zoster keratitis
Generic (originally Merck) · 1 drug in herpes zoster keratitis
Generic (originally Merck/Upjohn) · 1 drug in herpes zoster keratitis
Generic (originally Schering) · 1 drug in herpes zoster keratitis
Hannover Medical School · 1 drug in herpes zoster keratitis
Harrow Health · 1 drug in herpes zoster keratitis
Novartis · 1 drug in herpes zoster keratitis
Pfizer · 1 drug in herpes zoster keratitis
Tufts Medical Center · 1 drug in herpes zoster keratitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in herpes zoster keratitis:

Cite this brief

Drug Landscape (2026). herpes zoster keratitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/herpes-zoster-keratitis. Accessed 2026-06-10.

herpes zoster keratitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing